Phenotypes for C1qtnf6 MGI:6363630 MGI Mouse

N

• at 8 weeks of age, mice show no differences in antibody production against thymus-dependent and -independent antigens relative to wild-type controls

• at day 42 after primary type-II collagen (IIC) immunization, the number and % of CD4⁺ T cells in inguinal lymph nodes (LNs) is normal and the IIC-specific proliferative response of inguinal LN cells is unaffected, suggesting normal T cell priming

increased B cell number ( J:227217 )

• at day 42 after primary type-II collagen (IIC) immunization, the B220⁺ B-cell population is significantly expanded in inguinal LNs relative to that in wild-type controls

increased IgG level ( J:227217 )

• at day 42 after primary type-II collagen (IIC) immunization, the serum IIC-specific IgG level is significantly higher than that in wild-type controls

increased susceptibility to type III hypersensitivity reaction ( J:227217 )

• following induction of an IgG-mediated cutaneous reverse passive Arthus (RPA) reaction, vascular permeability is significantly enhanced relative to that in wild-type controls, as quantified by eluted Evans blue dye

abnormal complement pathway ( J:227217 )

• in vitro complement activation assays using LPS-coated plates revealed that alternative pathway (AP) activity (assayed in GVB/Mg²⁺ EGTA buffer) is specifically enhanced in mutant sera relative to wild-type sera, as determined by C3b deposition

• membrane attack complex (MAC) formation under AP activation conditions is enhanced in mutant sera; however, C3 and factor B levels are comparable to those in wild-type sera

• reconstitution experiments showed that monomeric exogenous recombinant human CTRP6 (rhCTRP6) specifically inhibits AP activation by LPS in a dose-dependent manner

abnormal complement protein level ( J:227217 )

• at day 42 after primary type-II collagen (IIC) immunization, the deposition of C3b in the ankle joints is significantly higher than that in wild-type controls

increased circulating complement protein level ( J:227217 )

• at day 7 after primary type-II collagen (IIC) immunization, plasma concentrations of C3a and C5a are significantly higher than those in wild-type controls

increased susceptibility to experimental autoimmune encephalomyelitis ( J:227217 )

• following immunization with the MOG_35-55 peptide, mice show a comparable incidence of EAE with a significantly higher severity score than wild-type controls at 22-28 days after immunization

increased susceptibility to induced arthritis ( J:227217 )

• following induction of mild collagen-induced arthritis (CIA), 6-8 week-old mice show a comparable incidence of arthritis with an earlier onset, a higher severity score, more severe pathological changes in ankle joints (proliferation of synovial lining cells, infiltration of inflammatory cells and bone destruction associated with pannus formation), and higher serum type-II collagen (IIC)-specific IgG levels than wild-type controls at day 42 after primary IIC immunization

• following induction of mild anti-collagen antibody-induced arthritis (CAIA), mice show increased incidence of arthritis with higher severity scores than wild-type controls at days 6-9 after anti-IIC mAb injection